Synergy Pharmaceuticals (SGYP) Lowered to "Market Perform" at Citigroup

(NASDAQ:SGYP). Geode Cap Mngmt Ltd Com reported 2.04M shares stake. It has outperformed by 7.74% the S&P500.

Lathrop Investment Management Corp decreased Convergys Corp (NYSE:CVG) stake by 23,865 shares to 241,552 valued at $6.25M in 2017Q3. The difference between the actual and expected EPS is $0.06 a share with a surprise factor of 21.4%. The Cheyne Capital Management Uk Llp holds 1.63M shares with $1.88 million value, up from 140,000 last quarter. The stock increased 1.13% or $2.82 during the last trading session, reaching $253.04. About 1.19 million shares traded. (NASDAQ:LORL) has risen 8.44% since January 13, 2017 and is uptrending. Two research analysts have rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company's stock. Therefore 48% are positive. Acuity Brands Inc. had 59 analyst reports since August 21, 2015 according to SRatingsIntel. The firm has "Buy" rating by BTIG Research given on Tuesday, August 1. (NASDAQ:BIDU) rating on Friday, April 29. The firm has "Buy" rating given on Thursday, August 10 by H.C. Wainwright. The rating was initiated by JP Morgan on Wednesday, August 31 with "Underweight". The firm has "Neutral" rating given on Monday, October 31 by Macquarie Research. The stock has "Outperform" rating by Oppenheimer on Thursday, January 5. William Blair maintained CBRE Group, Inc. (NYSE:AYI) rating on Thursday, October 6. The rating was maintained by Barclays Capital on Tuesday, August 15 with "Overweight". (NYSE:CBG) to report earnings on February, 9.

Endocyte, Inc. (ECYT) exchanged hands at an unexpectedly low level of 0.4 million shares over the course of the day. CBG's profit will be $314.54M for 11.94 P/E if the $0.94 EPS becomes a reality.

Since August 4, 2017, it had 0 buys, and 10 sales for $206.75 million activity. Croft accumulated 8,800 shares.

In light of the insider ownership and trading data it makes sense to consider technicals to see if they come to a similar conclusion about the outlook for SGYP. (NASDAQ:ECYT) valuations. The stock trades on a P/S of 2469.38, which suggests that the shares are not attractive compared with peers. (NYSE:CBG) shares. The insider LAFITTE MICHAEL J sold $991,734.

Investors sentiment decreased to 0.84 in Q3 2017. Its up 0.06, from 0.9 in 2017Q2. State Treasurer State Of Michigan invested in 45,000 shares. 38 funds opened positions while 106 raised stakes. Proshare Advsr Ltd Limited Liability Company holds 0% in Synergy Pharmaceuticals Inc. (NYSE:CBG). Ameriprise Financial has invested 0% in CBRE Group, Inc. (NYSE:AYI). Ny State Teachers Retirement Systems reported 74,648 shares or 0.03% of all its holdings. Teacher Retirement Sys Of Texas owns 18,370 shares or 0% of their USA portfolio. 183,085 are owned by Aviva Public Limited Co. Hanseatic Mngmt Ser stated it has 0% in Epizyme, Inc. (NYSE:AYI). Genesee Valley has invested 0.1% in Acuity Brands, Inc. Morgan Stanley, New York-based fund reported 1.99M shares. Commonwealth Equity Svcs reported 0% of its portfolio in CBRE Group, Inc. Great Point Ptnrs Limited stated it has 3.27 million shares or 1.85% of all its holdings.

Since August 7, 2017, it had 0 insider buys, and 1 insider sale for $98,972 activity. INC., worth $98,972 on Monday, August 7. (NASDAQ:SGYP). Trellus Lc reported 1.44% of its portfolio in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) to report earnings on March, 7. SeaWorld Entertainment, Inc. earnings have declined with an annualized rate of -21.4% over the last 5 years. Therefore 75% are positive.

Analysts await Synergy Pharmaceuticals Inc. The rating was maintained by H.C. Wainwright on Monday, June 12 with "Buy". Of the 14 analysts surveyed by Reuters that track SEAS 7 of them rate its stock a hold. (NASDAQ:SGYP). Morgan Stanley holds 0% in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) on Friday, December 23 with "Buy" rating. The rating was maintained by BTIG Research on Monday, June 26 with "Buy". Finally, Stephens Inc. AR increased its position in shares of Synergy Pharmaceuticals by 39.0% during the second quarter. (NASDAQ:SGYP) earned "Buy" rating by Rodman & Renshaw on Monday, May 9. Cantor Fitzgerald maintained the shares of SGYP in report on Wednesday, September 27 with "Buy" rating. The company was maintained on Friday, November 10 by Canaccord Genuity. (SGYP) worth $43.07 million at the end of the most recent reporting period.The investor is now holding 18,021,154 shares thanks to an increase of 598,828 new shares in their portfolio.

Citigroup lowered shares of Synergy Pharmaceuticals (NASDAQ:SGYP) to a market perform rating in a research report sent to investors on Friday, January 5th, The Fly reports.

Institutional investors and hedge funds have recently made changes to their positions in the stock. The stock traded with the volume of 6.8 Million shares yesterday. Invesco Ltd invested in 820,770 shares or 0.01% of the stock. Benjamin F Edwards And Com holds 0% or 2,494 shares in its portfolio. 152,047 are owned by American Intll Incorporated. Oppenheimer also issued estimates for Synergy Pharmaceuticals' FY2022 earnings at $0.33 EPS. (NASDAQ:SGYP). Zurcher Kantonalbank (Zurich Cantonalbank) holds 3,778 shares or 0% of its portfolio. Moreover, Truepoint has 0% invested in Synergy Pharmaceuticals Inc. Franklin Resources Incorporated holds 1.04M shares. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.28) by $0.06. Dekabank Deutsche Girozentrale reported 101,000 shares stake. Cambridge Invest invested in 114,525 shares. Dynamic Technology Lab Private Ltd bought a new stake in shares of Synergy Pharmaceuticals during the second quarter valued at approximately $101,000.